Combined Immunotherapy with Intracavital Injection of Activated Lymphocytes, Monocyte-derived Dendritic Cells and Low-dose OK-432 in Patients with Malignant Effusion

Anticancer Research

Volumn 23, Issue 6 A, 2003, Pages 4459-4465

  Morisaki, Takashi ^a   Matsumoto, Kotaro ^a   Kuroki, Hideo ^a   Kubo, Makoto ^a   Baba, Eishi ^a   Onishi, Hideya ^a   Tasaki, Akira ^d   Nakamura, Mitsunari ^b   Inaba, Syoichi ^c   Katano, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Sada Hospital   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

^d NONE

Author keywords

Activated T lymphocyte; Adoptive immunotherapy; Ascites; Dendritic cells; OK 432; Pleuritis

Indexed keywords

ANTINEOPLASTIC AGENT; PICIBANIL; RECOMBINANT COLONY STIMULATING FACTOR;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CYTODIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARCINOMATOSIS; CASE REPORT; CLINICAL PROTOCOL; CONFERENCE PAPER; CONTROLLED STUDY; DENDRITIC CELL; DISEASE MARKER; DRUG DOSE REGIMEN; FEMALE; HUMAN; LIFE EXPECTANCY; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; PLEURA EFFUSION; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASCITIC FLUID; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MIDDLE AGED; PANCREATIC NEOPLASMS; PICIBANIL; PILOT PROJECTS; PLEURAL EFFUSION, MALIGNANT; STOMACH NEOPLASMS; T-LYMPHOCYTES;

EID: 0345303903     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Baker AR and Weber JS: Treatment of maliganat ascites. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer; Principles and Practice of Oncology. Philadelphia: JB Lippincott, pp2255-2261, 1993.
2. Parsons SL, Watson SA and Steele RJ: Malignant ascites. Br J Surgery 83: 6-14, 1996.
3. Sadeghi B, Arvleux C, Glehen O, Beaujard AC, Rivoire M, Baullax J, Fontaumard E, Brachet A, Caillot JL, Faure JL, porcheron J, Peix JL, Francois Y, Vignal J and Gilly FN: Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE I Multicentric Prospective Study. Cancer 88: 358-363, 2000.
4. Torisu M, Katano M, Kimura Y, Itoh H and Takesue M: New approach for management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 93: 357-364, 1983.
5. Katano M and Torisu M: New approach to management of maliganat ascites with a streptococcal preparation, OK-432. II Intraperitoneal inflammatory cell-mediated tumor cell destruction. Surgery 93: 365-373,1983.
6. Katano M and Morisaki T: The past, the present and future of the OK-432 therapy for patients with malignant effusions. Anticancer Res 18: 3917-3926,1998.
7. Kitsuki H, Katano M, Ikubo A, Morisaki T, Anan K, Tanaka M and Torisu M: Induction of inflammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion: role of interferon-gamma in enhancement of surface expression of ICAM-1 on tumor cells in vivo. Clin Immunol Immunopathol 78: 283-290, 1996.
8. Kitsuki H, Uchiyama A, Yoshida T and Torisu M: OK-432-induced enhancement of ICAM-1 expression on tumor cells positively correlates to therapeutic effects for malignant effusion. Clin Immunol Immunopathol 71: 89-95,1994.
9. Chang AE, Geiger JD, Sondak VK and Shu S: Adoptive cellular therapy of malignancy. Arch Surg 128: 1281-1290, 1993.
10. Ravaud A, Legrand E, Delaunay MM, Bussieres E, Coulon V, Cany L, Huet S, Verdier D, Kind M, Chomy F, Bui BN and Gualde N: A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma. Br J Cancer 71: 331-336,1995.
11. Yee C, Thompsosn JA, Byrd D, Riddell SR, Roche P, Celis E and Greenberg PD: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistance, migration, and antitumor effect of transferred T cells Proc Natl Acad Sci USA 99: 16168-16173, 2002.
12. Lodge PA, Jones LA, Bader RA, Murphy GP and Salgaller ML: Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 60: 829-833, 2000.
13. Shift A, Friedl J, Dubsky P, Bachleiner̂Hofmann T, Schueller G, Zontsich T, Benkoe T, Radelbauer K and Brostjan C: Dendritic cell-based vaccination in solid cancer. J Clin Oncol 21: 135-142, 2003.
14. Guermonprez P, Valladeau J, Laurence Z, Théry C and Amigorena S: Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20: 621-667, 2002.
15. Piccioli D, Sbrana S, Melandri E and Valiante NM: Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 195: 335-341, 2002.
16. Becker Y: Dendritic cell activity against primary tumors: an overview. In Vivo 7: 187-191, 1993.
17. Kuroki H, Morisaki T, Matsumoto K, Onishi H, Baba E, Tanaka M and Katano M: Streptococcal preparation OK-432: a new maturation factor of monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother. 52: 561-568, 2003.
18. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG and Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 2: 52-58, 1996.
19. Lambert LA, Gibson GR, Maloney M, Durell B, Noelle RJ and Barth Jr RJ: Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 61: 641-646, 2001.
20. Candido KA, Shimizu K, McLaughlin JC, Kunkel R, Fuller JA, Redman BG, Thomas EK, Nickoloff BJ and Mulé JJ: Local administration of dendritic cells inhibits established breast tumor growth: Implication for apoptosis-inducing agents. Cancer Res 61: 228-236, 2001.
21. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G and Trinchieri G: Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 195: 327-333, 2002.
22. Revy P, Sospedra M, Barbour B and Trautmann A: Functional antigen-independent synapses formed between T cells and dendritic cells. Nat Immunol 2: 925-931, 2001.
23. Kondo T, Cortese I, Markovic-Plese S, Wandinger KP, Carter C, Brown M, Leitman S and Martin R: Dendritic cells signal T cells in the absence of exogenous antigen. Nat Immunol 2: 932-938, 2001.
24. Mätrten A, Ziske C, Bjorn S, Renoth S, Weineck S, Buttgereit P, Schakowski F, von Rücker A, Sauerbruch T and Schmidt-Wolf IGH: Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations J Immunother 24: 502-510, 2001.
25. Brocker T: The role of dendritic cells in T cell selection and survival. J Leukoc Biol 66: 331-335, 1999.
26. Thèry C, Duban L, Segura E, Vèron E, Lantz O and Amigorena S: Indirect activation of naive CD+4 T cells by dendritic cell-derived exosomes. Nat Immunol 3: 1156-1162, 2002.